Integrase Inhibitor resistance during antiretroviral therapy failure

• Research type

  Research Study

• Full title

  Assessment of HIV drug resistance during failure of Dolutegravir-based antiretroviral therapy

• IRAS ID

  297278

• Contact name

  Ravindra Gupta

• Contact email

  rkg20@cam.ac.uk

• Sponsor organisation

  University of Cambridge

• Duration of Study in the UK

  0 years, 11 months, 28 days

• Research summary

  People with HIV who take effective antiretroviral treatment (ART) become virologically suppressed after an approximate period of 6 month. Current recommendations indicate the use of the drug "Dolutegravir", an integrase inhibitor to treat all HIV patients. One key obstacle to HIV patients failing treatment and becoming unsuppressed is the emergence of drug resistance. There is limited data out of the sub-Saharan Africa on the emerging patterns of drug resistance. We aim to characterise these resistance patterns in HIV patients failing integrase inhibitor-based therapy.

• REC name

  North West - Liverpool Central Research Ethics Committee

• REC reference

  21/NW/0128

• Date of REC Opinion

  20 Apr 2021

• REC opinion

  Favourable Opinion